Skip to content
lifestyle.goodsciencing.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Vor Biopharma
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 5, 2026
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29, 2026
Telitacicept: Vor Bio Completes MG Phase 3 Enrollment, Expands to Ocular MG
September 8, 2026
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 4, 2026
Vor Bio To Participate in Upcoming September Conferences
September 1, 2026
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 3, 2026
Vor Bio Appoints David Zaccardelli to Board of Directors
July 7, 2026
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
May 14, 2026
1
2
Next Page
→